- Oncology
- ER+/HER2-Breast Cancer -
- Phase 3
An investigational oral PROTAC estrogen receptor (ER) degrader.
Vepdegestrant is being co-developed with Pfizer.
Arvinas is dedicated to advancing cancer care by developing PROTAC protein degraders for a variety of cancers and neurologic diseases.
Learn about our clinical stage development programs by selecting a compound below.
Click here to explore our full pipeline of PROTAC protein degraders.
An investigational oral PROTAC estrogen receptor (ER) degrader.
Vepdegestrant is being co-developed with Pfizer.
An investigational oral PROTAC B-cell lymphoma 6 (BCL6) degrader.
An investigational intravenous PROTAC Kirsten rat sarcoma (KRAS) degrader.
An investigational oral PROTAC androgen receptor (AR) degrader.
An investigational oral PROTAC leucine-rich repeat kinase 2 (LRRK2) degrader.
You are now leaving arvinasmedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.
This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.
By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).
If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.